Thought Leader

Mission of the MASLD Community

Dedicated to fostering collaboration, driving innovation, and improving outcomes for patients living with Metabolic Associated Steatotic Liver Disease.

Engage with MASLD/MASH Experts in Your Region

Connect with regional specialists for personalized guidance, professional training, and continuous support in MASLD/MASH.

Expert Insights

Benefit from expert-driven resources, including podcasts, publications, and practical tools designed for clinicians and patients.

Tailored Education for Your Community

Join your regional community network, where education is tailored to meet local needs. Collaborate with peers from local and regional communities, share knowledge, and drive impactful changes together.

Explore Our Events

Explore Our Events

Featured MASLD/MASH Educators

play

Elizabeth Alqueza

PA-C

Elizabeth Alqueza, PA-C is a board certified Physician Associate at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. She graduated from the University of Florida in 2004 with a Master of Physician Assistant Studies degree and subsequently completed the AASLD NP/PA Clinical Hepatology Fellowship. Elizabeth has worked in a variety of inpatient and outpatient settings with a strong commitment to patient care. Currently working at BIDMC Liver Center, Elizabeth has 5 years of dedicated experience in Hepatology. Her practice focuses primarily on steatotic liver disease, including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Elizabeth is an active member of Gastroenterology and Hepatology Advanced Practice Providers.

play

Michelle Barnett

PA-C, MPAS, DFAAPA

Michelle Barnett is a highly experienced physician assistant specializing in patient-focused and evidence-based hepatology at Peak Gastroenterology Associates in Colorado Springs, Colorado. The most rewarding part of her position includes educating patients and collaborating with other GI advanced practice providers to enhance care for the growing MASLD/MASH population. She is now a subinvestigtor for hepatology clinical trials with Peak in Colorado Springs. With over 30 years in the GI and liver communities, she has held leadership roles, including serving as President of the Colorado Academy of Physician Assistants (CAPA) and receiving CAPA's Physician Assistant of the Year award. She is a national speaker and has given lectures for the AAPA, GHAPP and AANP. A graduate of Wichita State University and the University of Nebraska, Michelle has been recognized with the DFAAPA distinction and honors such as the Crohn’s and Colitis Foundation's IBD internship and the International Foundation for Gastrointestinal Disorders Ally Award. Passionate about holistic care, she incorporates lifestyle strategies like nutrition, yoga, and meditation into her practice. Outside of work, Michelle enjoys hiking, travel, musical theater, and supporting her favorite Colorado sports teams.

play

Sherona Bau

NP

Sherona Bau graduated from University of California, Los Angeles in 2008, with Master of Science in Nursing dual program specialized in Acute Care Nurse Practitioner and Clinical Nurse Specialist. In 2010, she has joined UCLA Pfleger Liver Institute and Asian Liver Cancer Center working as an outpatient Nurse Practitioner specializing in liver diseases including viral hepatitis, hepatobiliary diseases, alcohol related liver diseases, Metabolic Dysfunction-Associated Steatotic Liver Disease/Steatohepatitis, autoimmune liver diseases, and hepatocellular carcinoma. Since 2016, she has been a guest lecturer at UCLA School of Nursing for Master Entry Clinical Nurse (MECN) and MSN Adult/Gero Acute Care program. She is also a preceptor for Adult/Gero Acute Care Program. She participated in Hepatitis C Screening in the Community Churches to promote awareness of hepatitis C and the importance of treatment of hepatitis C. She also participates in Patient Symposium at UCLA to give a lecture to update care of the liver transplant patients. She is also a faculty of Gastroenterology Hepatology Advanced Practice Provider (GHAPP) since 2018 and a speaker for both GHAPP National meeting and Regional GHAPP in Los Angeles. Since 2013, she has published total 14 research papers and case report including the most recent three are Recommendations for the Management of MASH by Advanced Practice Providers in the US, Clinicians and Patients Confront Practical Issues in Wilson Disease, and Overview of chronic Hepatitis B management.

MASLD/MASH Learning Center

Latest News & Blogs

Healthy mitochondria attenuate metabolic dysfunction-associated steatohepatitis by restoring cell metabolism

October 2025

Metabolic dysfunction-associated steatohepatitis (MASH) has become a major global health issue. Mitochondrial damage plays a crucial role in the development and progression of MASH. Therefore, it is speculated that mitochondrial transplantation therapy, which could replace dysfunctional mitochondria with normal ones, might potentially restore the liver cell metabolism of MASH. In palmitate-damaged AML-12 hepatocytes, exogenous mitochondria could eliminate lipid deposits and recover cell...

Read More arrow

Semaglutide for the treatment of MASH: reaching into the ESSENCE of cardio-metabolic health?

October 2025

Metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis poses a significant clinical challenge, especially given its strong association with obesity and type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated impressive results in managing obesity and T2DM, prompting interest in their potential therapeutic role for MASH with fibrosis. The ESSENCE trial recently investigated the effectiveness of once-weekly semaglutide in patients with...

Read More arrow

Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials

October 2025

CONCLUSION: The IMPG statements provide for the first time guidelines to promote consensus among liver pathologists for the histopathological evaluation and scoring of liver biopsies for MASH clinical trials. Furthermore, they may be used to inform supervised machine learning algorithms for quantitative MASLD histology assessments.

Read More arrow

Hepatocellular Carcinoma: from Screening to Therapy

October 2025

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a leading cause of cancer-related death worldwide. The incidence is increasing globally, primarily due to the rising prevalence of chronic liver diseases. While chronic viral hepatitis (HBV, HCV) and alcohol abuse have traditionally been considered the main risk factors, metabolic dysfunction-associated steatohepatitis (MASH) is increasingly gaining importance, especially in Western industrialized nations. In the vast...

Read More arrow

Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction-Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide

October 2025

CONCLUSIONS: In this post hoc exploratory analysis, MASH resolution and fibrosis improvement were associated with body weight reduction, improved glycemic control, and normalization of liver fat. Weight reduction and metabolic improvements with tirzepatide treatment potentially contributed to disease modification in MASH.

Read More arrow

Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis

October 2025

CONCLUSIONS: SGLT2 inhibitor and incretin-based agents improved fibrosis in MASH, with weight loss being a significant mediator. Targeting multiple incretin pathways, especially involving glucagon receptors, may offer greater MASH resolution. Dose-dependent effects were more prominent for MASH resolution than fibrosis improvement, indicating potential weight-loss-independent anti-fibrotic pathways.

Read More arrow

Semaglutide (Wegovy) for MASH

October 2025

No abstract

Read More arrow

Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression

October 2025

CONCLUSIONS: Significant molecular and immune alterations occur in disease progression of MASLD to MASH, reflecting both localized hepatic changes and systemic immune dysregulation. The identified transcriptomic signatures provide a promising tool for fibrosis prediction and monitoring, underscoring the need to target early disease mechanisms for improved diagnosis and therapeutic strategies.

Read More arrow

Retatrutide Improves Steatohepatitis in an Accelerated Mouse Model of Diet-Induced Steatohepatitis with a Fructose Binge

October 2025

Fructose consumption contributes to metabolic dysfunction-associated steatohepatitis (MASH). Retatrutide is a novel triple receptor agonist that improves obesity and hepatic steatosis in humans. The aims of this study were to develop a shortened and clinically relevant dietary mouse model of diet-induced steatohepatitis, and to evaluate the effects of a retatrutide intervention in this model. C57BL/6N mice were subjected to a single fructose binge (10 mg/g body weight), or a new 31-day mouse...

Read More arrow

Clinical Predictors of Progression From Metabolic Dysfunction-Associated Steatotic Liver Disease to Cirrhosis: A Narrative Review

October 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) continues to affect many people around the globe and may increase the likelihood of liver-related morbidity and mortality. Early identification of individuals at risk for progression to liver cirrhosis is crucial to the mitigation of the disease effects. This review aims to summarize the current evidence on clinical factors predicting MASLD progression to cirrhosis. A comprehensive literature search was conducted in PubMed,...

Read More arrow

Involvement of ferroptosis in metabolic dysfunction-associated steatohepatitis-related liver diseases

October 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD), as a metabolic liver disease, is emerging as the most prevalent chronic liver disease worldwide. Metabolic dysfunction-associated steatohepatitis (MASH) is the severe form of MASLD, which progresses from simple steatosis to an inflammatory state, even fibrosis and hepatocellular carcinoma. Accumulating evidence has proved that cell death is a hallmark of MASH, while the specific pathogenesis remains unclear. Several cell deaths,...

Read More arrow

Exploring multiorgan mitochondrial dysfunction in the switch toward progressive MASLD in AMLN mice

October 2025

Hepatic mitochondrial maladaptation features the transition from metabolic dysfunction-associated steatotic liver disease (MASLD) to Steatohepatitis (MASH) up to fibrosis/cirrhosis. However, it is still unexplored whether mitochondrial alterations also affect adipose tissue, muscle and heart during disease progression. C57Bl/6 mice were fed an AMLN diet to recapitulate the human MASLD spectrum. In the liver, TEM depicted a progressive morphologic dysfunction of mitochondria, which appeared...

Read More arrow

Effect of Non-Statin Lipid-Lowering Therapy on Hepatic Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review

October 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are significant health concerns affecting a large segment of the population and are known to be associated with adverse cardiovascular outcomes. As a result, various lipid-lowering medications are commonly employed in clinical practice to address the elevated cardiovascular risk in these patients. This systematic review summarizes the current evidence on emerging...

Read More arrow

Reevaluating the causal link between liver fat and hyperglycaemia

October 2025

CONCLUSION: The absence of a causal relationship between hepatic steatosis and glycaemic traits suggests that hyperglycaemia in metabolic dysfunction-associated steatotic liver disease may involve additional mechanisms beyond liver fat accumulation.

Read More arrow

Healthcare costs and treatment patterns associated with glucagon-like peptide 1 receptor agonist use among patients with metabolic dysfunction-associated steatohepatitis

October 2025

Aim: While only recently approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), many patients with MASH have taken glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of comorbid Type 2 diabetes (T2D) or obesity. This real-world study evaluated treatment patterns, weight loss, healthcare resource utilization, and costs among patients with MASH who initiated GLP-1 RAs. Materials & methods: In a linked electronic health records (Veradigm Network...

Read More arrow

Sterile inflammation in MASH: emerging role of extracellular RNA and therapeutic strategies

October 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its advanced form, metabolic dysfunction-associated steatohepatitis (MASH), are major global health issues involving metabolic dysfunction, hepatic lipotoxicity, and chronic inflammation. A key driver of MASH pathogenesis is sterile inflammation, a non-infectious immune response triggered by molecules that are released from injured or dying liver cells. These molecules termed as damage-associated molecular patterns (DAMPs),...

Read More arrow

Hepatic steatosis and pyroptosis are induced by the hepatitis B virus X protein via B56α-METTL3 interaction-mediated m6A modification of the NLRP3 mRNA

October 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is one of the fastest-growing chronic liver diseases and is characterized by excessive steatosis, inflammation, and progressive liver injury. The hepatitis B virus (HBV) X protein (HBx) is a major viral factor that contributes to the onset and progression of MASH. Emerging evidence highlights the role of epigenetic modifications, particularly N6-methyladenosine (m6A), as prevalent modifications of mRNAs that play crucial roles in MASH...

Read More arrow

TLR4 promotes liver fibrosis in metabolic dysfunction-associated steatohepatitis by a mechanism independent of hepatocytes and inflammatory cells

October 2025

In metabolic dysfunction-associated steatotic liver disease (MASLD), liver fibrosis is the most important prognostic factor, and fibrosis can lead to hepatic cirrhosis and cancer. In the liver toll-like receptor 4 (TLR4) signaling promotes fibrosis. To investigate the role of TLR4 in the development of MASLD, we used a mouse model of MASLD, and we deleted the Tlr4 gene either in the whole body or selectively in inflammatory cells or hepatocytes. Mice with a whole-body deletion of Tlr4 developed...

Read More arrow

Reliable monitoring of patients with MASLD using imaging: a systematic literature review and meta-analysis on measurement repeatability

October 2025

As treatments for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) emerge, patient eligibility assessment and monitoring is increasingly important. To assess the reliability of non-invasive imaging technologies in MASLD, we systematically reviewed the literature for studies on technical repeatability. PubMed Central and MEDLINE were searched (2015-2025) for studies in MASLD that examined the repeatability of: magnetic resonance (MR)-derived iron-corrected T1 (cT1),...

Read More arrow

beta-sitosterol attenuates hepatic lipid accumulation and fibrosis via NLRP3 signaling in MASH mice

October 2025

Β-sitosterol (SIT), a natural phytosterol, has not been fully explored for its therapeutic potential in metabolic dysfunction-associated steatohepatitis (MASH). In this study, MASH was induced in mice via a high-fat, high-cholesterol (HFHC) diet, and lipid accumulation in HepG2 cells was triggered with oleic acid (OA), while the role of the NLRP3 inflammasome was explored in NLRP3-knockout (NLRP3^(-/-)) mice treated with or without SIT. SIT treatment significantly alleviated HFHC-induced hepatic...

Read More arrow